Zydus Cadila becomes second Indian pharma with US IND for GK activator in diabetes
This article was originally published in Scrip
Executive Summary
Zydus Cadila, one of India’s leading healthcare companies announced that it has received an IND approval from the US FDA for ZYGK1, an orally administered small molecule glucokinase activator for Type 2 diabetes. The move reinforces Zydus' transition from its heavy dependence on generics to its ambitions as a research-led company. It also makes Zydus the second Indian company exploring the glucokinase activation space, alongside Advinus.